However, it should be noted that long-term Dll4 inhibition in mice resulted in vascular neoplasms [148], suggesting that this mode of therapy cannot immediately be converted into clinical use, although there are clinical trials with Demcizumab, a humanized Dll4 antibody, which appears to be tolerated although with some side effects, including hypertension [149]. This evidence concerns the gene DLL4 and vascular neoplasm.